Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol

Objective Data on the intensity of statin therapy for patients with acute myocardial infarction (MI) and very low baseline low-density lipoprotein (LDL) cholesterol level are lacking. We sought to assess the impact of statin intensity in patients with acute MI and LDL cholesterol <70 mg/dL. Methods A total of 1,086 patients with acute MI and baseline LDL cholesterol <70 mg/dL from the Korea Acute Myocardial Infarction Registry-National Institute of Health database were divided into less intensive statin (expected LDL reduction <40%, n=302) and more intensive statin (expected LDL reduction ≥40%, n=784) groups. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCEs), a composite of cardiac death, MI, revascularization occurring at least 30 days after admission, and stroke, at 12 months. Results After 1:2 propensity matching, differences were not observed between less intensive (n=302) and more intensive statin (n=604) groups in incidence of cardiac death (0.3% vs. 0.3%) and hemorrhagic stroke (0.3% vs. 0.5%, p=0.727) at 12 months. Compared with the less intensive statin group, the more intensive statin group showed lower target-vessel revascularization (4.6% vs. 1.8%, p=0.027) and MACCE (11.6% vs. 7.0%, p=0.021). Major bleeding was not different between less intensive and more intensive statin groups (1.0% vs. 2.6%, p=0.118). Conclusion More intensive statin therapy was associated with significantly lower major adverse cardiovascular events in patients with acute MI and very low LDL cholesterol compared with less intensive statin therapy.

[1]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[2]  Y. Ohashi,et al.  High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD) , 2018, Circulation.

[3]  M. Jeong,et al.  Effects of Statin Intensity on Clinical Outcome in Acute Myocardial Infarction Patients. , 2018, Circulation journal : official journal of the Japanese Circulation Society.

[4]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[5]  A. Keech,et al.  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial , 2017, The Lancet.

[6]  Ju Han Kim,et al.  Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol ≤ 50 mg/dl. , 2017, The American journal of cardiology.

[7]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[8]  A. Guerrero,et al.  2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines - Executive Summary , 2016, ASEAN heart journal : Official journal of the ASEAN Federation of Cardiology.

[9]  Ju Han Kim,et al.  Multicenter Cohort Study of Acute Myocardial Infarction in Korea - Interim Analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[10]  Improve-It Investigators Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[11]  Jong Chun Park,et al.  Comparing High-Intensity Versus Low-to Moderate-Intensity Statin Therapy in Korean Patients with Acute Myocardial Infarction , 2014 .

[12]  P. Ridker,et al.  Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. , 2014, Journal of the American College of Cardiology.

[13]  Mary G. George,et al.  An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[14]  Xiang Wang,et al.  Cholesterol Levels and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis , 2013, Stroke.

[15]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction , 2013, Nature Reviews Cardiology.

[16]  Takeshi Kimura,et al.  Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[17]  J. Cho,et al.  Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol. , 2011, Journal of the American College of Cardiology.

[18]  Kyung Hoon Cho,et al.  Low-density lipoprotein cholesterol level in patients with acute myocardial infarction having percutaneous coronary intervention (the cholesterol paradox). , 2010, The American journal of cardiology.

[19]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[20]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[21]  J. Liao Safety and efficacy of statins in Asians. , 2007, The American journal of cardiology.

[22]  K. Eagle,et al.  Effect of statin use in patients with acute coronary syndromes and a serum low-density lipoprotein, 2005, The American journal of cardiology.

[23]  R. D'Agostino Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[24]  Á. Avezum,et al.  Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.

[25]  M. Ezekowitz,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[26]  P D Cleary,et al.  Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. , 2001, Journal of clinical epidemiology.

[27]  XiangWang,et al.  Cholesterol Levels and Risk of Hemorrhagic Stroke , 2013 .

[28]  G. Levine,et al.  ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions , 2011 .

[29]  J. LeLorier,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[30]  A. Gotto,et al.  The evolving role of statins in the management of atherosclerosis. , 2000, Journal of the American College of Cardiology.

[31]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .